checkAd
    Startseite > Aktien > Corcept Therapeutics > Nachrichten
    Corcept Therapeutics Aktie
    32,00
     
    EUR
    +1,04 %
    +0,33 EUR
    Letzter Kurs 11:39:58 Tradegate
    31,52
     
    EUR
    128 STK
    Geldkurs 12:12:19
    32,14
     
    EUR
    126 STK
    Briefkurs 12:12:19
    ISIN: US2183521028 · WKN: 529882 · SYM: HTD · USA

    Neueste Nachrichten

    Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
    03.06.24 · globenewswire · Corcept Therapeutics
    Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
    28.05.24 · globenewswire · Corcept Therapeutics
    Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
    01.05.24 · globenewswire · Corcept Therapeutics
    Corcept Completes Enrollment in Phase 4 CATALYST Trial
    29.04.24 · globenewswire · Corcept Therapeutics
    Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
    24.04.24 · globenewswire · Corcept Therapeutics
    Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
    22.04.24 · globenewswire · Corcept Therapeutics
    Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
    15.04.24 · globenewswire · Corcept Therapeutics
    Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
    08.04.24 · globenewswire · Corcept Therapeutics
    Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
    01.04.24 · globenewswire · Corcept Therapeutics
    Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
    15.02.24 · globenewswire · Corcept Therapeutics
    Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
    15.02.24 · globenewswire · Corcept Therapeutics
    Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
    08.02.24 · globenewswire · Corcept Therapeutics